Deep Learning AI and future hybrid algorithm development for the prediction of future dementia developing risk

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Header Abstract Content Author and article information References Comments

Record: found
Abstract: found
Conference Proceedings: found

Is Open Access

Deep Learning AI and future hybrid algorithm development for the prediction of future dementia developing risk

Published

conference-abstract

Author(s): Ira Ronit Hebold Haraldsen ¹ ^, ²

Publication date (Electronic, pub): 6 October 2023

Publisher: REPO4EU

Conference name: RExPO23

Conference date: 25-26 October 2023

Keywords: Artificial intelligence, Deep Learning, Machine Learning, Simulation, Hybirds and synthetic Data

Bookmark

Abstract

While the potential of AI and simulation in healthcare has been widely recognized for many years, their integration into clinical practice remains limited. This lack of widespread adoption in neurological healthcare is not primarily due to a shortage of advanced computer technologies. Instead, it can be attributed to several key factors: i)Interdisciplinary Conceptual Understanding: One major challenge is the absence of a comprehensive interdisciplinary understanding of algorithms related to brain diagnostics. Effective AI and simulation tools require a deep integration of medical knowledge with computer science expertise: i) Another critical aspect is the availability of extensive neurological data. There is a need for robust infrastructure for storing and managing large sets of sensitive neurological data, ensuring privacy and security. ii) Transparency and Standardization. To gain trust and acceptance in the medical community, standardized internal revision procedures and transparency standards are essential. This includes clear documentation of how AI and simulation algorithms arrive at their conclusions. iii) Real-World Evidence: Demonstrating the real-world effectiveness of AI and simulation tools is crucial. Decisionmakers require solid evidence that these technologies can improve patient outcomes and reduce healthcare costs. Addressing these challenges is vital for the cost-efficient implementation of personalized diagnostics and treatment in neurological healthcare through group-based AI solutions and individualized simulation technologies. The European Commission's "White Paper on Artificial Intelligence" in 2020 acknowledges the transformative potential of merging AI and simulation, often referred to as 'hybriding,' for the future of personalized healthcare.mHowever, despite this recognition, the practical integration of these approaches into clinical settings remains underdeveloped. To unlock the transformative potential of hybrid AI and simulation technologies in personalized neurology, there is an urgent need for new cross-sector knowledge and educational initiatives. These initiatives should focus on overcoming the challenges related to interdisciplinary collaboration, data management, transparency standards, and real-world applications.

Content

Author and article information

Conference

Publisher: REPO4EU

Publication date (Electronic, pub): 6 October 2023

Affiliations

[1 ] Oslo University Hospital (Norway) ( https://ror.org/00j9c2840)

[2 ] www.AI-Mind.eu;

Author information

Ira Ronit Hebold Haraldsen https://orcid.org/0000-0002-6908-5423

Article

DOI: 10.58647/REXPO.23027

SO-VID: 42564d0d-1bba-40eb-9bde-39ee7fc50898

License:

Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

Conference name: RExPO23

Conference number: 2

Conference location: Stockholm, Sweden

Conference date: 25-26 October 2023

History

Product

REPO4EU

References

Siontis George C M, Sweda Romy, Noseworthy Peter A, Friedman Paul A, Siontis Konstantinos C, Patel Chirag J. Development and validation pathways of artificial intelligence tools evaluated in randomised clinical trials. BMJ Health & Care Informatics. Vol. 28(1)2021. BMJ. [Cross Ref]
Jones David T., Kerber Kevin A.. Artificial Intelligence and the Practice of Neurology in 2035. Neurology. Vol. 98(6):238–245. 2022. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]

Comments

Comment on this article

[1] Siontis George C M, Sweda Romy, Noseworthy Peter A, Friedman Paul A, Siontis Konstantinos C, Patel Chirag J. Development and validation pathways of artificial intelligence tools evaluated in randomised clinical trials. BMJ Health & Care Informatics. Vol. 28(1)2021. BMJ. [Cross Ref]

[2] Jones David T., Kerber Kevin A.. Artificial Intelligence and the Practice of Neurology in 2035. Neurology. Vol. 98(6):238–245. 2022. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]

Deep Learning AI and future hybrid algorithm development for the prediction of future dementia developing risk

Conference

Affiliations

Author information

Article

History

Product

Categories

Comment on this article